Citations

Clear

813 citation(s) found for "He, Helen".

Transplantid.net: A Pilot Crowdsourced, Living, Online Library of Resources for the Teaching and Practice of Transplant Infectious Diseases
Azar, Marwan M. , Tsai, Helen , Vergidis, Paschalis , Harris, Courtney E. , Anjan, Shweta , Barros, Nicolas , Belga, Sara , Chuang, Sally T, Czeresnia, Jonathan Mamber , Goel, Shipra , İnce, Dilek , Luk, Alfred , Obeid, Karam M. , Swaminathan, Neeraja , Puius, Yoram A , Azar, Marwan M , Tsai, Helen , Vergidis, Paschalis , Harris, Courtney E , Anjan, Shweta , Barros, Nicolas , Belga, Sara , Czeresnia, Jonathan M , Ince, Dilek , Luk, Alfred , Majeed, Aneela , Multani, Ashrit , Obeid, Karam M , Swaminathan, Neeraja , Majeed, Aneela

Mayo Clinic

Open Forum Infectious Diseases | February 14, 2023 | Volume: 10 | Issue: 2 | Pages: No page available

10.1093/ofid/ofad081 | PMID 36861087 Get It

Abstract The field of transplant infectious diseases is rapidly evolving, presenting a challenge for clinical practice and trainee education. Here we describe the construction of transplantid.net, a free online library, crowdsourced and continuously updated for the dual purpose of point-of-care evidence-based management and teaching.
Abstract 53: Long-term Treatment Risk Of Hemorrhage In Unruptured Brain Arteriovenous Malformation Patients
Nelson, Jeffrey , Koroknay-Pál, Päivi , Lawton, Michael T. , Moayeri, Nicole, Mohr, J.P. , Zaroff, Jonathan G. , Zhao, Yuanli , Kim, Helen , Salman, Rustam Al‐Shahi , Flemming, Kelly D. , Hess, Christopher Paul , Hetts, Steven W. , Laakso, Aki , Lanzino, Giuseppe , McCulloch, Charles E. , Morgan, Michael K. , Stefani, Marco Antônio

Mayo Clinic

Stroke | February 2, 2023 | Volume: 54 | Issue: Suppl_1 | Pages: No page available

10.1161/str.54.suppl_1.53 Get It

Introduction: The long-term effects of interventional treatment (with surgery, stereotactic radiosurgery, or endovascular embolization) for unruptured brain arteriovenous malformations (uBAVM) are uncertain. We address this in a large multi-center international cohort study comparing risk of intracranial hemorrhage (ICH) in the treated and untreated course of uBAVM patients. Methods: We pooled individual patient data (n=3,291) from 10 cohorts and imputed missing data. Survival analysis was performed from time of uBAVM diagnosis to intracranial hemorrhage (ICH) using Cox models, stratified by cohort, censoring at death or last follow-up, and including BAVM interventional treatment as a time-varying covariate. We tested for an interaction of treatment with follow-up time, then estimated the association of interventional treatment with ICH, adjusting for propensity quintile. Individual treatment propensity scores were calculated using logistic regression with Spetzler-Martin grade, sex, diagnosis age and year, cohort, and presence of presenting symptoms (seizures, headaches, and/or deficits). Results: Median cohort age was 36 years, 48% were female, and 77% received ≥1 treatment modality for uBAVM during follow-up. 373 ICH occurred during 32,054 person-years of follow-up (median=6.6y), for an ICH rate of 1.16 per 100 P-Y. Overall, treatment was not associated with risk of ICH (HR=1.12, 95% CI=0.89-1.51, p=0.33). However, we observed a strong interaction between treatment and follow-up time (p<0.001): between 0-1 year, treatment was associated with higher risk of ICH (HR=3.48, 95% CI: 2.26-5.37, p<0.001); between 1-10 years, we found no association between treatment and risk of ICH (HR=1.02, 95% CI: 0.73-1.45, p=0.87); after 10 years, treatment was associated with a lower risk of ICH (HR=0.46, 95% CI: 0.30-0.70, p<0.001). Survival curves for untreated and treated courses crossed around 17 years. Conclusion: After accounting for treatment propensity for uBAVM, we found an initial increased risk of ICH in the treated relative to untreated course, which continually declined over time with survival curves crossing around 17 years. These results require confirmation in a randomized controlled trial of uBAVM with long-term follow-up.
Abstract 121: Prospective Symptomatic Hemorrhage Rates And Functional Outcomes In Trial Eligible Cavernous Angiomas With Symptomatic Hemorrhage
Mandrekar, Jay , Harmsen, William S. , Nelson, Jeffrey , Stadnik, Agnieszka , Torbey, Michel , Thompson, Richard E. , Treine, Kevin, Awad, Issam A, Flemming, Kelly D. , Kim, Helen , Lanzino, Giuseppe , Huang, Judy , Hanley, Daniel F. , Awad, Issam A.

Mayo Clinic

Stroke | February 2, 2023 | Volume: 54 | Issue: Suppl_1 | Pages: No page available

10.1161/str.54.suppl_1.121 Get It

Background: Cerebral cavernous angiomas with symptomatic hemorrhage (CASH) carry highest rebleed rates and are targeted for novel interventions. A multisite clinical trial readiness project (clinicaltrials.gov NCT03652181) aims to identify clinical and functional changes over time in trial eligible CASH patients. Methods: Adult patients from 5 high volume centers with a CASH in the prior year and no planned surgical intervention were enrolled. In addition to demographic, clinical, and imaging review, patients underwent baseline, 1 year and 2 year NIH-stroke scale (NIHSS), modified Rankin scale (mRS), Euro-QOL 5D-3L (EQ-5D-3L) and EQ VAS (visual analog score), and PROMIS 29 assessments. Recurrent symptomatic hemorrhages (SH) were verified. We assessed the hemorrhage rate, change in scores/scales over time, and determined which scales/scores were most affected in patients with SH. Results: 123 patients completed baseline assessments and were prospectively followed (60.9% female; mean age 44.1 years; 39.1% familial; 41.5% brainstem location). As of reporting date, 89 of 104 (86%) and 58 of 76 (76%) cases have completed assessments. There were 16 SHs during 147 patient-years of follow up (10.9% per patient year). At baseline, 111 (90.2%) of patients had NIHSS 0-2 and 77 (62.6%) patients had mRS baseline 0-1 which improved to 40 (95.2 %) and 43 (75.4%) at 2 years. At baseline, 54 (43.9%) of patients had at least one moderate to severely abnormal PROMIS-29 domain compared to 13 (26.5%) at 2 years. EQ-5D-3L baseline demonstrated a moderate proportion of patients reporting some difficulty with pain (48.8%), anxiety (41.5%), and activity (41.5%) which improved to 28%, 30%, and 34% respectively at 2 years. Patients with a prospective SH were more likely than those without recurrent SH at 2 years to display mild functional decline (0.5 SD) of most PROMIS-29 domains, a mRS of 2 or higher and an abnormal EQ- self-care (P<0.05). Other scales/scores were not significantly different between the groups. Conclusion: We report SH rate and functional outcome at baseline and rates of changes during 2 years in trial eligible CASH patients. The PROMIS-29, mRS, and EQ-self-care domains were most discriminative in patients with recurrent SH. No test was 100% specific.
Abstract 114: Changes In Quantitative Susceptibility Mapping On Magnetic Resonance Imaging During Prospective Follow-Up Of Cavernous Angiomas With Symptomatic Hemorrhage In Trial Readiness Project
Stadnik, Agnieszka , Torbey, Michel , Mendoza‐Puccini, Carolina , Thompson, Richard E. , Awad, Issam A. , Hage, Stephanie , Lee, Justine C. , Flemming, Kelly D. , Kim, Helen , Huang, Judy , Koenig, James I. , Carroll, Timothy , Girard, Romuald , Shenkar, Robert , Hanley, Daniel F.

Mayo Clinic

Stroke | February 2, 2023 | Volume: 54 | Issue: Suppl_1 | Pages: No page available

10.1161/str.54.suppl_1.114 Get It

Background: Quantitative susceptibility mapping (QSM) is a measure of iron content, and ≥6% increase in QSM has been correlated with new hemorrhage in previously stable cavernous angiomas. Longitudinal changes in QSM are not known in cavernous angiomas with symptomatic hemorrhage (CASH) with high rates of rebleeding and are the targets of novel pharmacotherapies. In a prospective multisite Trial Readiness project (clinicaltrials.gov NCT03652181), QSM is longitudinally assessed. Methods: Trial eligible subjects with CASH in the prior year and not undergoing lesion resection or radiation, were enrolled. Mean QSM of CASH lesion was acquired at baseline and at 1 and 2 year planned follow-ups. Relative change in mean lesional QSM during each follow-up year was assessed, and any symptomatic hemorrhage (SH), asymptomatic changes (AC; defined as subclinical bleed or growth) in the lesion during the same epoch. Results: Paired QSM assessments were completed to date in 99 CASH lesions (67 year 1, and 32 year 2) and are reported herein. Four SH and 6 ACs occurred during 1 st follow-up year, and 3 SH during 2 nd year. QSM increased in 54 lesion-years, decreased in 44, and remained stable in 1. The % lesional QSM change in year 1 was significantly higher than that observed in year 2 (mean +9.33, SD 37.52 vs. +5.20; SD= 24.86; p=0.05; Spearman correlation ρ -0.36). CAs with clinical SH or AC had a significantly higher % QSM change than lesions without (mean +28.03, SD 17.77 vs. +4.97, SD= 34.75; p=0.0014). All 13 lesions with SH/AC demonstrated a QSM increase ≥6% while 31 of 86 (36%) lesions with no clinical events had a ≥6% QSM increase. Conclusion: QSM change of ≥6% is present in every CASH lesion manifesting a new SH or AC (100% specificity), and is more common than clinical events (3.4X higher sensitivity). The biomarker can hence be used as a more sensitive categorical outcome than SH or AC in clinical trials of novel therapies aimed at bleeding in CASH lesions. Effect of an intervention on % QSM change may also be proposed as a time-averaged difference between 2 arms using a repeated measures analysis implemented as an unadjusted linear mixed model. These results are the basis of application for certification by the U.S F.D.A. of QSM as a monitoring biomarker of drug effect in CASH.
Transplant of organs from donors with positive SARS‐CoV‐2 nucleic acid testing: A report from the organ procurement and transplantation network ad hoc disease transmission advisory committee
Goldman, Jason D. , Pouch, Stephanie M. , Woolley, Ann E. , Booker, Sarah E. , Jett, Courtney , Fox, Cole, Berry, Gerald J. , Dunn, Kelly E., Kittleson, M. , Lee, Dong Heun , Levine, Deborah J. , Marboe, Charles C. , Taimur, Sarah , Te, Helen S. , Fisher, Cynthia E. , Sellers, Marty T. , Levi, Marilyn E. , Klassen, David K. , Danziger‐Isakov, Lara , Lee, Dong Heun , Marklin, Gary , Trindade, Anil J , Michaels, Marian G , La Hoz, Ricardo M , Danziger-Isakov, Lara , Pouch, Stephanie M , Berry, Gerald J , Ho, Chak‐Sum , Razonable, Raymund R. , Anesi, Judith A. , Wood, R. Patrick, Zaffiri, Lorenzo , Hoz, Ricardo M. La

Mayo Clinic

Transplant Infectious Disease | January 25, 2023 | Volume: 25 | Issue: 1 | Pages: No page available

10.1111/tid.14013 | PMID 36694448 Get It

AbstractBackgroundDecisions to transplant organs from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) nucleic acid test‐positive (NAT+) donors must balance risk of donor‐derived transmission events (DDTE) with the scarcity of available organs.MethodsOrgan Procurement and Transplantation Network (OPTN) data were used to compare organ utilization and recipient outcomes between SARS‐CoV‐2 NAT+ and NAT– donors. NAT+ was defined by either a positive upper or lower respiratory tract (LRT) sample within 21 days of procurement. Potential DDTE were adjudicated by OPTN Disease Transmission Advisory Committee.ResultsFrom May 27, 2021 (date of OTPN policy for required LRT testing of lung donors) to January 31, 2022, organs were recovered from 617 NAT+ donors from all OPTN regions and 53 of 57 (93%) organ procurement organizations. NAT+ donors were younger and had higher organ quality scores for kidney and liver. Organ utilization was lower for NAT+ donors compared to NAT– donors. A total of 1241 organs (776 kidneys, 316 livers, 106 hearts, 22 lungs, and 21 other) were transplanted from 514 NAT+ donors compared to 21 946 organs from 8853 NAT– donors. Medical urgency was lower for recipients of NAT+ liver and heart transplants. The median waitlist time was longer for liver recipients of NAT+ donors. The match run sequence number for final acceptor was higher for NAT+ donors for all organ types. Outcomes for hospital length of stay, 30‐day mortality, and 30‐day graft loss were similar for all organ types. No SARS‐CoV‐2 DDTE occurred in this interval.ConclusionsTransplantation of SARS‐CoV‐2 NAT+ donor organs appears safe for short‐term outcomes of death and graft loss and ameliorates the organ shortage. Further study is required to assure comparable longer term outcomes. image
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
DuBois, Steven G. , Krailo, Mark , Bender, Julia Glade , Buxton, Allen, Laack, Nadia N. , Randall, R. Lor , Chen, Helen X., Seibel, Nita L. , Boron, Matthew, Terezakis, Stephanie , Hill‐Kayser, Christine E. , Hayes, Andrea, Teot, Lisa A., Womer, Richard B. , Arndt, Carola, Lessnick, Stephen L. , Eutsler, Eric P., Janeway, Katherine A. , Glade-Bender, Julia , Laack, Nadia N Issa , Reid, Joel M , Rakheja, Dinesh , Womer, Richard , Lessnick, Stephen L , Crompton, Brian D , Kolb, E Anders , Reed, Damon R , Janeway, Katherine A , Gorlick, Richard , Seibel, Nita L , Randall, Robert Lor , Hayes, Andrea A., Reid, Joel M. , Rakheja, Dinesh , Crompton, Brian D. , Daldrup-Link, Heike , Reed, Damon R. , Görlick, Richard

Mayo Clinic

Journal of Clinical Oncology | January 20, 2023 | Volume: 41 | Issue: 11 | Pages: 2098-2107

10.1200/jco.22.01815 | PMID 36669140 Get It

PURPOSE Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to determine if the addition of the IGF-1R monoclonal antibody ganitumab to interval-compressed chemotherapy improves event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma. METHODS Patients were randomly assigned 1:1 at enrollment to standard arm (interval-compressed vincristine/doxorubicin/cyclophosphamide alternating once every 2 weeks with ifosfamide/etoposide = VDC/IE) or to experimental arm (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy). A planned sample size of 300 patients was projected to provide 81% power to detect an EFS hazard ratio of 0.67 or smaller for the experimental arm compared with the standard arm with a one-sided α of .025. RESULTS Two hundred ninety-eight eligible patients enrolled (148 in standard arm; 150 in experimental arm). The 3-year EFS estimates were 37.4% (95% CI, 29.3 to 45.5) for the standard arm and 39.1% (95% CI, 31.3 to 46.7) for the experimental arm (stratified EFS-event hazard ratio for experimental arm 1.00; 95% CI, 0.76 to 1.33; 1-sided, P = .50). The 3-year overall survival estimates were 59.5% (95% CI, 50.8 to 67.3) for the standard arm and 56.7% (95% CI, 48.3 to 64.2) for the experimental arm. More cases of pneumonitis after radiation involving thoracic fields and nominally higher rates of febrile neutropenia and ALT elevation were reported on the experimental arm. CONCLUSION Ganitumab added to interval-compressed chemotherapy did not significantly reduce the risk of EFS event in patients with newly diagnosed metastatic Ewing sarcoma, with outcomes similar to prior trials without IGF-1R inhibition or interval compression. The addition of ganitumab may be associated with increased toxicity.
An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Donskov, Agnete Overgaard , Mackie, Sarah , Hauge, Ellen‐Margrethe , Gutiérrez, Carlos Enrique Toro , Hansen, Ib Tønder , Hemmig, Andrea Katharina , Maas, Aatke van der , Gheita, Tamer A. , Nielsen, Berit Dalsgaard , Douglas, Karen, Matteson, Eric L. , Matza, Mark , Ocampo, Vanessa , Grainger, Rebecca , Bran, Andrea, Appenzeller, Simone , Goecke, Annelise, Colmán, Nelly , Keen, Helen , Kuwana, Masataka , Gupta, Latika, Salim, Babur , Harifi, Ghita , Erraoui, M. , Ziadé, Nelly , Al-Ani, Nizar Abdulateef, Ajibade, Adeola , Frølund, Line L. , Yates, Max , Pimentel-Quiroz, Víctor R. , Lyrio, André Marun , Sandovici, Maria , Geest, Kornelis S. M. van der , Brouwer, Elisabeth , Dejaco, Christian , Keller, Kresten Krarup , Gupta, Latika , Mackie, Sarah Louise , Gheita, Tamer , Conway, Richard , Monti, Sara , Sattui, Sebastian E , Grainger, Rebecca , Keen, Helen , Kuwana, Masataka , Gupta, Latika , Ziade, Nelly , Knitza, Johannes , Pimentel-Quiroz, Victor R , Van der Geest, Kornelis S M , Dejaco, Christian , Keller, Kresten Krarup , Yates, Max , Conway, Richard , Rezuş, Elena , Dasgupta, Bhaskar , Monti, Sara , Sattui, Sebastian E. , Gromova, Margarita Aleksandrovna , Helliwell, Toby

Mayo Clinic

Rheumatology | January 12, 2023 | Volume: 62 | Issue: 8 | Pages: 2797-2805

10.1093/rheumatology/keac713 | PMID 36637182 Get It

Abstract Objectives To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR &gt;2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing &gt;25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials.
Challenges and solutions to sustaining paediatric weight management programs in the United States
Christison, Amy L. , Kumar, Seema , Novick, Marsha B. , Stratbucker, William, Sweeney, Brooke , Vidmar, Alaina P. , Kirk, Shelley, Vidmar, Alaina , Christison, Amy , Ariza, Adolfo J. , Fernandez, Cristina, Santos, Melissa

Mayo Clinic

Clinical Obesity | January 12, 2023 | Volume: 13 | Issue: 3 | Pages: No page available

10.1111/cob.12577 | PMID 36631245 Get It

SummaryPaediatric weight management (PWM) programs in the United States (US) face challenges in providing sustainable multidisciplinary care for patients. The aim of this study was to report PWM program approaches to sustaining program delivery. A survey of 39 PWM programs was administered to identify challenges and solutions to program sustainability. Common and useful strategies for optimizing reimbursement for services included the use of applicable reimbursable diagnostic codes and management, billing for assessments and non‐medical personnel services, and the use of hospital outpatient department clinic billing. Increasing clinical breadth and capacity was achieved by offering telemedicine and other services, such as psychotherapy, pharmacotherapy, and metabolic and bariatric surgery, as well as active management of schedules. Securing institutional and extramural funding was also reported. One of the positive changes during the pandemic was the fast adoption of telemedicine services. Although delivering sustainable evidence‐based multidisciplinary PWM under the current US payment models has its challenges, PWM programs implement practical operational strategies to support this work.
Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma
Desai, Sanjal H. , David, Kevin A. , Bachanová, Veronika , Goyal, Gaurav , Dorritie, Kathleen , Kenkre, Vaishalee P. , Arai, Sally , Chang, Cheryl , Fusco, Brendon , Hatic, Haris, Saba, Raya , Harris, Elyse I., Shah, Harsh , Murphy, Jacob, Ansell, Stephen M. , Jagadish, Deepa, Diefenbach, Catherine , Iyenger, S., Rappazzo, K. C., Choi, Yun Young , Nowakowski, Grzegorz S. , Advani, Ranjana H. , Micallef, Ivana N. , David, Kevin , Bachanova, Veronika , Goyal, Guarav , Sumransub, Nuttavut , Shah, Harsh , Ansell, Stephen M , Advani, Ranjana H , Desai, Sanjal , Diefenbach, Catherine S , Spinner, Michael A. , Kahl, Brad S. , Azzi, Jacques Mario , Ibrahim, Uroosa , Murphy, Jacob, Orellana‐Noia, Victor M. , Mishra, Rahul

Mayo Clinic

American Journal of Hematology | January 11, 2023 | Volume: 98 | Issue: 3 | Pages: 464-471

10.1002/ajh.26827 | PMID 36629030 Get It

AbstractClinical trials of novel salvage therapies have encouraging outcomes for relapsed/refractory transplant‐eligible classic Hodgkin lymphoma (R/R cHL) but comparison with conventional chemotherapy is lacking. Herein, we report the final analysis of a multicenter retrospective cohort of R/R cHL assessing outcomes by type of salvage therapy before autologous stem cell transplant (ASCT). R/R cHL patients who underwent ASCT at 14 institutions across the United States were included. Outcomes were compared among patients receiving conventional chemotherapy, brentuximab vedotin (BV) + chemotherapy, BV alone, and a checkpoint inhibitor (CPI)‐based regimens before ASCT. Study endpoints included event‐free survival (EFS), progression‐free survival (PFS), and overall survival (OS). All endpoints are defined from relapse. Of 936 patients, 728 received conventional chemotherapy, 73 received BV + chemotherapy, 70 received BV alone, and 65 received CPI‐based regimens prior to ASCT. When adjusted for time to relapse, pre‐ASCT response and use of BV maintenance, patients receiving CPI‐based regimens had superior 2‐year EFS compared to conventional chemotherapy, BV + chemotherapy, and BV alone (79.7, 49.6, 62.3, and 36.9%, respectively, p < .0001). Among 649 patients transplanted after 1 line of salvage therapy, CPI‐based regimens were associated with superior 2‐year PFS compared to conventional chemotherapy (98% vs. 68.8%, hazard ratio: 0.1, 95% confidence interval: 0.03–0.5, p < .0001). OS did not differ by pre‐ASCT salvage regimen. In this large multicenter retrospective study, CPI‐based regimens improved EFS and PFS compared to other salvage regimens independent of pre‐ASCT response. These data support earlier sequencing of CPI‐based regimens in R/R cHL in the pre‐ASCT setting.
Serologic and biochemical analyses of a variant Ae (E beta) ia polypeptide chain in D2.gD (H-2g2).
Hendrickson, Helen, Corser, Paula S., David, C S, Lafuse, William P.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 127 | Issue: 2 | Pages: 811-813

10.4049/jimmunol.127.2.811 Get It

Abstract Recombinant D2.Gd (KdAdBbJbEbCbSbDb) was derived from parental strains B6 (H-2b) and DBA/2 H-2d). Recent peptide studies and 2-D electrophoresis studies from other laboratories have shown that the Aed (E beta) chain of D2.GD is structurally different from the parental-derived chain. An antiserum (D2.GD X A. TFR5)F1 anti-DBA/2 was produced that detects an Ia specificity (Ia.50) in the I-E molecule formed by the parent Aed chain and lacking in the I-E molecule formed by the variant Aed. chain. The variant Ae chain could have derived either from a mutational event or an intracistronic cross-over.